Disease Diagnosis TRIZ Cases

Compact passively Q-switched frequency-doubled laser pulses generate transient vapor nanobubbles for fast, noninvasive malaria detection in field conditions.

Combining serum BDNF and CA125 with clinical data enables more reliable non-invasive endometriosis screening, diagnosis, and monitoring.

mRAGE biomarker screening improves sperm selection by detecting DNA fragmentation, oxidative stress, and mitochondrial dysfunction with less invasive testing.

A multi-marker panel detects glycocalyx disruption without destructive imaging, enabling earlier diagnosis and treatment guidance for vascular disease.

Urinary SAA2-derived peptide signatures enable non-invasive early detection and monitoring of systemic inflammation without blood draws.

Antibody-based detection of BIM-Bcl-2 and related heterodimers quantifies apoptosis pathway interactions to guide BH3 mimetic selection.

A buffer-releasing reagent cap and integrated LFA tube cut test-kit parts, waste, and packaging cost while keeping sample flow reliable.

Single-time-point Cystatin B and clusterin testing distinguishes progressive from stable CKD earlier than creatinine, SDMA, or biopsy.

CD73-deficient DP8α Tregs provide a non-invasive way to predict acute GvHD risk and guide treatment after allo-HSCT.

Blood S100A8 measurement enables earlier, less invasive endometriosis diagnosis and monitoring, especially in minimal and mild stages.

A calcium-free sperm motility test reveals CatSper functional defects, simplifying male infertility diagnosis and avoiding ineffective treatment.

A lateral flow hybrid peptide assay detects NMDA autoantibodies in blood for rapid, low-cost screening of chronic cerebral ischemia.

Saliva protein markers such as PK, MMP-9, and S100 proteins enable faster, more precise classification of mild versus advanced periodontitis.

CD5, CD14, and CD163 marker profiling separates pro-inflammatory dendritic cells from overlapping subsets and links their proportion to disease severity.

Engineered alpha-synuclein mutants suppress spontaneous aggregation while preserving seed-triggered detection for earlier, more accurate synucleinopathy assays.

Biofluid biomarkers such as GFAP, UCHL-1, Tau, and NF-L improve SAE diagnosis and help predict cognitive outcomes earlier.

B-cell exosome levels in blood help identify cancer patients more likely to benefit from immune checkpoint blockade with lower toxicity risk.

Gender-stratified IgG cutoff values and p-value-screened food panels improve psoriasis trigger-food testing by reducing false positives.

High-pH sample pretreatment disrupts enzyme-antibody interference, improving assay sensitivity for lysosomal storage disease monitoring.

Combining sIFNAR2 assessment with MRI dissemination markers improves multiple sclerosis diagnosis and prognosis accuracy.

A 3-11 serum biomarker panel replaces biopsy to diagnose NASH and stage hepatic fibrosis with lower invasiveness and cost.

Protein and peptide biomarker panels improve early preterm birth risk assessment with high sensitivity and specificity from maternal samples.

Serial urine biomarker tracking over 14 days improves prediction of renal recovery after AKI and helps target dialysis-related care.

Specific antibodies targeting the NT-proBNP HXLG epitope improve canine heart disease detection and prognosis through precise biomarker measurement.

A multi-protein antigen panel detects blood autoantibodies to distinguish Alzheimer's from SCD, MCI, and other dementias.

Flow cytometry isolates adipose and blood cell populations to quantify VEGFR thresholds for selecting targeted angiogenic obesity therapy.

A unified CPS formula combines tumor and inflammatory cell PD-L1 counts to cut pathologist workload and improve anti-PD eligibility decisions.

Combining GFAP with additional neuroactive biomarkers enables faster, objective detection of mild to moderate brain injury from CSF or serum.

Multiple enzymes on a polymer-linked nanoparticle boost lateral flow antigen detection sensitivity while simplifying conjugate fabrication.

A multi-biomarker TBI assay combines H-FABP, IL-10, GFAP, NF-L, and S100B to improve recovery outcome prediction for clinical use.

Phospho-Drp1-Ser616 detection replaces slow platelet aggregometry with a rapid, lower-cost assay for antiplatelet response assessment.

Specific blood cholesteryl esters predict retinal omega-3 levels more reliably than diet or broad plasma lipid measures.

Molecular rotors entering RBCs reveal deformability distribution through fluorescence, improving vaso-occlusive risk assessment.

Combining tenascin C, apolipoprotein A-IV, and 1-methyladenosine improves biochemical recurrence detection in prostate cancer.

Saliva kynurenine testing enables non-invasive detection and monitoring of inflammation in acute COVID-19, long COVID, and PIMS.

An initial fluid sequestration chamber feeds a flow-based assay to cut contamination and speed point-of-care diagnosis while preserving sample accuracy.

Combined PCT and MR-proADM thresholds improve infection severity triage, treatment decisions, and mortality risk assessment.

A graphene oxide chip uses fluorescent antibodies and resistance change to detect low influenza viral loads with faster, simpler testing.

Two capillary flow paths split one sample to separately detect IgM and IgG, improving Lyme infection differentiation within 10 minutes.

Measures cytokine, chemokine, and growth factor output after IL-40 stimulation to assess activity and guide immune cell differentiation.

Screen cereblon-modifying compounds by tracking SALL4 degradation to identify cancer therapies with lower teratogenic risk.

Headspace gas analysis of animal body fluids uses a surface stress sensor to detect ketosis on site with higher throughput and less stress.

ITIH3 blood levels replace fluctuating clinical scores with an objective marker of myasthenia gravis activity and prognosis.

BMMF1 Rep protein detection uses monoclonal antibodies to improve early pancreatic cancer diagnosis by identifying inflammation-linked tissue changes.

Saliva PK, MMP9, S100A8, and Hb-beta measurements enable faster, more objective classification of mild versus advanced periodontitis.

Absorbance changes after deoxygenation enable rapid point-of-care identification of HbS or HbC and differentiation of sickle trait and disease.

ELISA detection of soluble or surface Cyr61 in blood or bone marrow improves identification of breast cancer CTCs and DTCs.

Demethylating tumor-cell STING before agonist treatment restores antigenicity and boosts melanoma T cell recruitment and response.

A biomarker panel enables faster, more accurate LVO stroke identification, reducing delays before mechanical thrombectomy.

A multiplex anti-porcine antibody assay detects donor antigens and recipient reactivity to help assess xenotransplant rejection risk.

Multiplex fluorescence biomarkers and digital pathology generate a prognostic score for Barrett's esophagus progression risk.

An initial blood volume is sequestered, then routed to a lateral flow assay and reservoir to cut contamination and speed point-of-care diagnosis.

A multi-antigen porcine antibody assay helps identify rejection risk in xenotransplant candidates by screening human antibodies across SLA targets.

Multi-marker analysis of PR, HER2, SIAH2, and FOXA1 improves DCIS recurrence risk prediction to guide treatment and avoid overtreatment.

Targeted fecal estrone-sulfate measurement with separative LC-MS improves ungulate pregnancy diagnosis accuracy without blood sampling.

Blood lipid metabolites replace liver biopsy to distinguish MASH from MASLD without inflammation and fibrosis using a non-invasive test.

EVtrap isolates and enriches plasma and serum vesicle proteins to distinguish pancreatic cancer from benign disease without biopsy.

C1QBP ELISA and IHC reagents help detect oral squamous cell carcinoma and relate protein expression to risk and prognosis.

An 11-TAAb panel uses NAPPA protein microarrays to improve early ovarian cancer detection while reducing false positives.

This case uses disease-specific BCR clonotypes in peripheral blood to reduce reliance on costly, invasive MRI and PET scans.

HPLC or antibody assays distinguish normal and abnormal insulin isomers, supporting responsive treatment without relying only on glucose.

Antibody-coated beads capture proteins, while lectin-labeled beads amplify glycan signals for selective, rapid glycoprofiling.

Tape stripping extracts stratum corneum metabolites to diagnose dandruff without invasive tissue damage.

Measuring 3-Indoxyl Sulfate levels in blood plasma to identify ADHD presence through objective metabolic analysis.

Time-lapse imaging measures cytokinesis timing to predict implantation potential and reduce multiple gestation risks.

Immunoluminometric sandwich assay detects MR-proANP concentrations in patient plasma samples to support clinical evaluation.

A fluorometric immunoassay detects anti-dsDNA antibodies using fluorescent dyes bound to immune complexes.

An exosome-derived proteomics platform quantifies APOA4, ITGB3, and CRP levels to differentiate healthy, mild cognitive impairment, and Alzheimer's stages.

Saliva-based mass spectrometry identifies metabolites, resolving the trade-off between analysis invasiveness and throughput.

Multiplexed biomarker analysis evaluates treatment responsiveness in renal cell carcinoma, addressing insufficient early detection efficiency and specificity.

A time-resolved fluorescent immunochromatographic test strip detects paclitaxel using monoclonal antibody-labeled microspheres.

Prostaglandin E2 binding moieties form complexes with blood samples to detect specific biomarker levels.

Detection molecules bind quorum sensing target molecules to identify sepsis pathogens, bypassing slow culture methods that delay targeted antibiotic treatment.

Selective labels bind reduced cysteine groups to assess protein oxidation states, replacing expensive HPLC equipment with accessible biochemical detection.

Modulating EZH2 activity with specific inhibitors restores MHC expression, reversing cancer-induced immune evasion.

Aβ22(pE)-42 peptide binds amyloid-beta antibodies in blood samples to enable dementia detection.

Extracting tumor biomarkers from lymphatic fluid resolves the sensitivity trade-off in blood-based liquid biopsies, enabling earlier cancer stage detection.

Ten protein markers predict cancer responsiveness to Type III receptor tyrosine kinase inhibitors.

RBC composite indices predict erythropoietin therapy responsiveness, resolving functional iron deficiency diagnosis challenges.

Serum PROK1 biomarkers replace traditional screening methods to resolve low prediction accuracy and reliability issues.

Quantifying HLA-DR expression on monocyte subsets resolves diagnostic subjectivity and improves immunotherapy response prediction.

GC/MS analysis of urine lipoarabinomannan replaces slow sputum cultures to accelerate nontuberculous mycobacterial infection diagnosis.

A biomarker panel detects protein levels in blood samples to distinguish malignant from benign tumors.

Liquid chromatography mass spectrometry detects specific cellular metabolites to resolve diagnostic accuracy limitations caused by complex autism etiology.